Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-16
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Thank you so much for joining us on our next session. I'm Michael Yee, Senior Biotechnology Analyst here at UBS, and we're excited to have the Chief Executive Officer of IDEA Biosciences here, Ujira Hata, with us. Idea is an exciting time right now because the company is on the brink of filing and getting potential approval for their lead drug. I say Daro, but Daro of a short tip for metastatic uveal melanoma, a small molecule with tremendous efficacy and positive phase through results. So that may happen in 2027 in the brink of your first approval. In addition, there's so much pipeline to talk about, I'm going to have to limit it in our 25-minute discussion because there's not enough time, and you're hosting an R&D analyst event later today as well. So, we get a little preview of that today. So, without further ado, maybe, Jero, you could set the table for us first to just, obviously, Talk about the most important things going on at IDEA, which perhaps you'll hear more later at the R&D Day, but set the table for us a little bit about your current pipeline.
Well, great. First, thank you, Mike, for hosting us, and also congratulations to UBS on the inaugural event in London this week. So idea of biosciences, as you mentioned, 2026 has been a transformational year for us. We filed our first NDA, also reported our top-line results in an oral presentation at ASCO several months ago. We also did recently announce the advancement of DLL3-TOPO-ADC into Phase III registrational studies, as well as positive second-line overall survival data in small cell lung cancer at ESMO just here recently. And Mike, as you noted, the updates are going to continue. We have our first London R&D Day later this afternoon at 5 p.m. London time, where we will showcase what we believe is a very deep pipeline in MTAP and CDKinsway. So hopefully a lot to talk about today, Mike. We look forward to the discussion.
Okay, so we'll preview it a little bit here in our session, but coming to the primary lead program, Darrow, for metastatic uveal melanoma, you filed the NDA. Uh, the filing presumably is for HLA to negative, uh, patients of which the phase three was, uh, enrolled and completed in. Um, so talk about where you are in that filing. When would be the expected approval and what do you expect the approval to look like?
Yes, so the NDA has been filed. We noted that that happened in the third quarter. It was towards the end of the third quarter. That was also filed under RTOR, so a rolling review submission process of the NDA. And our focus on the Phase III randomized study was in the HLA-A2 negative population in the first-line setting of metastatic melanoma. We have noted, based on our recent disclosures, that based on the mechanism of action, as well as the data that we had presented, we do believe derovacertib is relevant, irrespective of HLA-A2 status. So that is how we did proceed with the NDA filing with that specific mindset in place.
When you file it, and I've never filed an NDA, but you write out an indication, does it say HLA-2 negative in that exact filing indication?
Yeah, so as part of our NDA submission, the strategy that we are advancing is a focus on irrespective of HLA-2 status. But, you know, we would want to emphasize that we appreciate this will be a review issue with the FDA. Second is we will, in either scenario, have an NCN strategy in place for both the negative and the positive.
Have you completed the rolling NDA? Or maybe I might hear about that later today. I don't know. But what is the estimated PDUFA date and timing for approval?
Yes, we will learn on the PDUFA date here relatively soon. So at the time of NDA acceptance, we do anticipate it will be likely in that first half of next year timeframe. Okay.
Okay. And so when that occurs, you have filed for approval irrespective of HLA status. And most people on Wall Street would say, okay, wait a second. And just for those who may not know all the numbers, the reason why we're asking about this is because HLA-2 negative is around 50-50. You might give me a different number, but it's around 50% of the target population. Whereas Immunocore, another company that's actually here at this conference as well, is approved in HLA2 positive, the other 50%. And so while your indication would be going after a market that is not directly competing against Immunocore. Um, you do believe that you could get approval for both populations and therefore double your opportunity, double, because it is in the other subgroup. Uh, what, what most people and investors are with that, but that's not what the study was, uh, enrolling. That was HLA2 negative. What would be the reason and why would you say that, uh, you could get approval in both?
Yeah, so it's also, Michael, on the question around the prevalence or frequency of HLA-2 negative versus positive, we do believe the majority of the population is HLA-2 negative. We believe it's likely in that 60-40 to two-thirds, one-third range. Second, in terms of our reason why we believe this therapy is relevant to the broader population of metastatic even melanoma is because of its mechanism of action. So as a reminder, over 95-plus percent of this patient population, we believe, does have an activating mutation of gene AQ11, which turns on the PKC signaling pathway. So this is not a MOA. That's linked specifically to HLA-A2 status. So that's really probably the...
That is a factor of the currently approved drug, ChemTrack, is a TCR-based drug, which will have to do with whether or not your HLA status matches up with the drug in order to bind, in order to work. Yours is a small molecule. That doesn't have anything to do with that.
Exactly. Right. And then also the data that we presented to ESMO, I believe, corroborates that point. The HLA-2 status is not linked to the mechanism of action that Dorough Hissertid specifically addresses.
And how many patients were treated in that study?
So we had roughly about 100 patients worth of data. Roughly 20% of that was in the first line setting.
And how many patients were in the second line, excuse me, in the HLA-negative phase three?
So the, yeah, so the HLA-2 negative, so as a randomized study, so we had, you know, roughly in that 400 patient range.
So 200 have been treated and have randomized controlled data, approximately 100 in HLA-2 positive, of which 20% of it, so 20, were in the HLA-2 positive group. But so there is Safety data, that's important, efficacy data that aligns with... The same overall response rate and same PFS and general overall survival, crosstalk in person, open label, but it generally aligns with that.
Yes, it does. It generally aligns with that. You know, appreciate one is a randomized study. Obviously, also, you have to think about the ratio of the randomization for that randomized study. Correct. I think large, big picture related to PFS, obviously the OS data, single arm data versus randomized data. So there are going to be some differences there, but big picture, we do think the data negative and positive are generally various.
And then assuming we do get approval, just sticking with like the near term commercial opportunity, you think it is 60%, whereas KimTrack, maybe 40 to 50%. Now, I cover Immunocore and Immunocore's KimTrack launch was quite robust out of the gate, just to be fair. Very strong launch, relatively high priced drug, but of a strong survival benefit, and has approval and approvals and reimbursement around the world, a lot of countries, and is on pace to do approximately 400 and something million dollars. Do you believe that your launch would be no different in the U.S. because your price of your drug would probably be somewhere in the similar vicinity range? You have survival data, too, although that survival is not completed yet, so we need to answer that. But that the launch of that drug should be no different. You have a small molecule. They had an infusion. Your drug is even easier to administer. So what would you say about their launch and your launch?
Look, I think there's several parallels to ChemTrack that we have that I would say gives us confidence in this upcoming projected commercial launch. First is we are seeking first-line approval, similar to ChemTrack, and obviously that's going to have certain advantages as well. Also, as a reminder here, remember, you know, in this case, the indication is the diagnostic as well. So we don't have a situation where, at least for the mutation of GNA-Q11, there's not a diagnostic that we need as well to identify these patients. And thus far, in addition to getting frontline approval, we believe the other treatment options are not effective in relation to the data we saw. Based on the hazard ratio we've reported for PFS, and the response rate was, you know, approximately six times beyond what we saw in the control arm. So based on those set of facts, you know, we do anticipate a strong launch.
When Kymtrak was approved, I recall that they had an overall survival completion. Your phase three has completed PFS, and that date has been presented at ASCO, but the survival is still maturing. There's a trend in survival, I think you've said, but it has not completed. To what extent does survival play any role in the approvability of the drug or the fact that approval survival may not be in the label? Now, I'm not sure that a doctor would or would not prescribe the drug because of survival because there's no options, frankly, and this PFS is fantastic. But does FDA need survival for approval?
So for accelerated approval, based on the endpoints that we reached in alignment with the FDA, we do believe PFS is sufficient for accelerated approval. Mike, as you mentioned, OS will be upcoming. The guidance we've given is an interim OS readout in the middle of next year, and that continues to be the guidance that we have. But no, we do feel confident in the data we have based on the very robust hazard ratio that was recorded and PFS as the aligned endpoint for accelerated approval. Okay.
Yeah, it's accelerated approval, so survival register for confirmatory. Okay, so another thing to think about in terms of the profile, the drug, and the launch and comparing it to the revenue opportunity that ChemTrack has. So again, KimTrack is doing hundreds of millions of dollars. It's an HLA-2 positive. You think your market's a little bit bigger, 60%. Price of the drug could be similar. So again, Wall Street analysts are more than the same, yet you could be 2x because you could get use in HLA-2 positives. If you don't get the broad label, we'll see, would there be patients who could still access it through NCCN guidelines? And so that would be an opportunity. And would that take time for that to happen, or would that be pretty quick?
Yes, so assuming that we get approval and commercial launch, our plan would be to sequence our strategy and implementation of that in terms of NCN guideline process in fairly proximal nature to the anticipated approval. We do believe because this is an area of unmet need that there could be an opportunity for a fairly near-term review as part of that under NCN.
So that's our at least current thinking right now. I mean, it's a little unclear to me how fast this happened, but could that be something that happens in calendar 27?
Yes.
It could be in NCCN guidelines.
Well, the process that we would initiate as part of that. It doesn't happen until after you get approval.
Correct. And then you initiate the process. I'm not an expert in how long that process takes, because it's like a working group, the NCCN, that has to do that, and they only do it once or twice a year or something like that.
Yeah, so that process we anticipate will be several months. I think there, the question of the annual versus an ad hoc review, we do think, you know, some of the parameters to consider is that this is an area of very high amend deed. Okay. Yeah. All right.
Look forward to that opportunity and approval. And again, I always just say, well, we're going to talk a little bit more about that later today and the opportunity. So we're just giving a little preview of that. Now, the second thing that I've been very excited about, and I'm sure you're going to talk about it later today, too, is the fact that you've had a bunch of press releases this summer, recently, about your PRMT5. So we're going to talk about MTAP tumors. And your PRMT5 could be best in class. And it is currently in phase one testing. But importantly, you've also announced in these two press releases, a collaboration with Roche to combine your PRMT5 with their PanRAS and with their G12D. So Roche has got some pretty awesome drugs, and you have a third drug that could be synergistic. So talk about your PRMT5. People are familiar with Tango's product. Do you think your product is as good as Tango's product, and when are we going to get some data?
So we will share some clinical data in a few hours here later this afternoon that will include human PK, safety data, as well as human pharmacodynamic data. We will anticipate we'll have some patient case studies as well that we'll be able to share. And our view is that we do believe we have a potential best-in-class PRM25 inhibitor. And basically for us, the key parameters for that, Mike, as you know, first is that we do believe having a clean drug-drug interaction profile, in particular against CYP3-4, is critical to fulfill that criteria for best-in-class. And a big reason for that is we believe PRMT-5 is largely a combination agent, specifically in the indication of pancreatic cancer, in particular with PANRAS, with KRASG-12D. We recently also announced our new candidate earlier today related to CDKIN-2A ID-101, which we anticipate will be in the clinic first half of next year. The reason why this is important is that the majority of these targets that we just mentioned, at least the molecules that we are aware of, the metabolism path is largely mediated through CYP3E4. So now, from a drug-driven interaction perspective, we don't believe this is just about PANRAS, but all these other agents that are PMT5 inhibitor may want to be combined with, including standard-of-care chemotherapy and pancreatic cancer, What's CYP3A4 plays a key role, as well as, as you know, con meds that these patients may be on, where you also have to consider CYP3A4. So we do think that is a central TPP to have the best-in-class inhibitor. Second is, we believe CNS penetrance is not a favorable profile, because we don't believe there's a benefit, but could introduce a liability related to CNS-related tox. And then finally, third is MTA cooperative selective binding versus SAM cooperative, which we believe should translate into safety and what type of myelous suppression your molecule may or may not be seeing. And that's some of the data that we'll share here in several hours.
In order to show lack of drug-drug interactions, Um, what would you need to see? You need to basically show in combination that the two drugs in a phase one don't have changes in PK. And the only way to do that is that you somehow took your own drug and dosed it in someone who else who had another drug that had the same pathway. One of those would be potentially pan-ras drugs. So when you dose a niroxin or acid from Revolution Medicines and you dose with Tango's PRMT5, they do show PK changes, and that's very clear that that's due to an interaction. Would you need to dose your drug with diroxoracib in order to show that?
Yeah, so the view here, Mike, is that we've already been generating clinical data in combination with another molecule that is also CYP3-4-mediated, including ID397, our Matsui inhibitor. So that's some of the data that we plan to share here this afternoon. Okay. So we feel we've already seen data that supports this notion that we mentioned about not having that type of drug-drug interaction liability related to CYP3-4.
And is that literally should be the only de-risking factor to show that that should not impact duroxin or acid? If it was, I mean, you could dose some patients with duroxin or acid. I mean, the drug is out there, so technically you can go find some patients and do that pretty quickly. But just like conceptually, I'm not an expert in GDIs, but if you, other than dosing with those patients, which would be helpful data too, you're saying you've dosed with another CYP3A inhibitor and you don't see an interaction. So there you go.
So I think that's an important, I think the data we've generated is an important first step already that we've already answered the question. We will be generating data with Roche on PanRAS here shortly. So we should be dosing our first patient by the end of the year. We do know that several of these molecules that are tricomplex inhibitors via cyclophiline, the chemistry has some similarities, you know, across several of these molecules in the clinic. So we do think once we have that data with Roche, we'll be able to validate that as well. But we already have early clinical read that it does not appear we're at least driving acid-3 or liability with other drugs that we know are mediated through.
So on one hand, it's one step to show that you could have no drug drug interactions with another major blockbuster drug. Let's all be fair. Deroxoracib is accepted to be a pretty big drug. And if you could show that in combination, that would be one de-risking effect because the other one does seem to have some of those effects. The other is to show it that you could do that in combination with another panrass, which could be an exciting competitor to Xerox Rass, which is Roche's panrass. So Roche has a panrass. Uh, we think, although you could perhaps agree or not agree that they've treated a lot of patients with their pan-ras, so they have data internally. They think it's a pretty good pan-ras, could be as good as deroxiracid behind, but could be similar. And yet you're going to be in combination with that. Have you dosed patients together with that drug in the clinic in phase one? Has that started or it's about to start?
Yeah, so that dosing is going to be here in the very near term. So we do believe that we'll be able to dose our first patient by the end of the year, be able to answer that question. And we do think that will be an important indicator for other pan-RAS inhibitors like dirax and RASB as well. The one important piece, Mike, I think that we would emphasize, you know, we also did do preclinical evaluation of several of the paramtive inhibitors in the clinic, and our view is based on the data we generated was some of the drug-to-drug interaction that was reported would have been anticipated based on the preclinical data that we assert. So I would highlight here there's two aspects of DDI that you want to think about. One is the reversible IC50s for drug-drug interactions, including CYP34. The other is irreversible, which is also called time-dependent innovation. And you need to look at both to really have a sense of the potential DDI liability. So our view is the data that was reported was anticipated based on the preclinical evaluation, which is also why it gives us confidence that ours should have a very favorable DDI profile based on that preclinical support that it was anticipated. This was not sort of a finding that was outside of what would have been anticipated.
Let me explore that a little bit. So again, the idea that PRMT5, such as Tango, in combination with RevMed's PanRAS, clearly the efficacy is very exciting. That's great. This is why there's a lot of Wall Street enthusiasm around this pathway, and that by taking PRMT5 plus PanRAS, we get much higher efficacy and not a lot of added toxicity. Fantastic. If you can show that same type of efficacy and good side effect profile and not have to dose down duroxacid, that would be great. Perhaps we get similar or better efficacy because you are dosing down one of the key drivers of that. That would be great. It is the concept that you could also dose with chemo, is what you're saying, because there are first-line studies that I guess would happen, or in combination with the G12D and a pan-ras and your drug and like a triple mono, a triple all-oral regimen. Is that the idea? So, yeah.
So I think the commentary- Some people
think that the DDI issues, and again, this could be coming from the competitor, is not a big deal.
Yeah, so I think the CYP3 or CYP4 piece, I think the main point there was that that would be relevant beyond PanRES, right? It would also impact G12D, RCD kin-sway molecule we mentioned, as well as other standard care agents like chemotherapy that are also known to be mediated through CYP3 or CYP4. So big picture, our view is that it will make life simpler to be able to have a molecule that you don't have to consider the drug-drug interactions. I think just the other part, this is really just from our perspective, is, you know, clinical development is a long path, right? You're going to have to go into larger patient data sets, larger registrational trials. Uh, so at least our view in terms of a more favorable profile would be ideally one, uh, without a drug drug interaction. And we think that's independent of PRMT5, but that's more of a general statement, uh, in the pharmaceutical, uh, general industry.
Would you, do you, since this is a pretty big value creation. Opportunity for you. Do you think we could get combination data with your PRMQ5 and Roche's Pan-RAS in 2027? That could be a major medical conference in Chicago. I don't know.
Yeah, I mean, yeah, I think having an update on clinical data next year should be the objective. You know, we anticipate that the initial cohort, that based on the dose we've cleared for monotherapy for PRMT-5. As well as our current plan to start the pan-ras inhibitor at the Roche expansion dose, we anticipate that first cohort may very well be the expansion dose. So this is not going to be a very long dose escalation. It may be one cohort. And we do anticipate to see fairly meaningful activity at that cohort. Think about it, right?
So if Roche has been running the pan-ras at different doses, they're finding a dose that is efficacious and reasonably well-tolerated. That is their dose that they're excited about, whatever dose that is. You would just take, in combination, your drug and add it onto that in an expansion cohort. They're going to do monotherapy, and they would do combination at that expansion cohort, pick a random 400 milligrams. I'm just picking a number. I don't know the doses. And so it should be pretty quick, because it's like one cohort, you should be able to know what's happening.
Exactly. Okay. Yeah.
All right. Well, I hope to see that data and the monotherapy data because Roche, you know, talks a little bit about it, but the idea if they do have a competitive one would be exciting for you. Does this also apply to lung cancer as well? Because many people think the PDAC market is running away with throxoracid, just to be fair. Rev Med just did record numbers in the first month. And that Tango is already trying to initiate a phase three in PDAC. So people feel like the PDAC market opportunity is running away down the field. And yet, Roshan, you guys don't have any data in PDAC yet. Does lung cancer, does this apply to lung cancer as well?
Yeah, so it can apply to lung cancer, Mike. I would say our top priority is pancreatic cancer, primarily because we believe it represents about 40% of that population. Second, we do continue to believe that a first-line strategy in frontline PDAC still remains very open, especially related to MTAP and RAS intersection, which is substantial. Long cancer is going to be a smaller population. So you want to take roughly 15% and divide it by three. So it's about 5% of lung cancer because you have to think about the co-alteration population. But clearly, an opportunity that could be pursued as well. Okay.
I agree. So first-line PDAC in combination would be an obvious study that you'd want to get going as soon as possible. Like I said, Tango is trying to get it going to those patients in phase three. Okay. Last one in our last couple of minutes. So again, I appreciate it, and you'll go through more of this later this afternoon. Um, the DLL three antibody drug conjugate landscape and DLL three overall is an exciting area. Um, uh, and Amgen has been, uh, doing quite well with tarlatumab and small cell lung cancer. And, um, they are also in first line maintenance. Great for Amgen. It's looking to be a multibillion dollar drug. We cover that stock. They've been doing great. Meanwhile, Xilab has been putting up SENDATA, and they've started, they're in a pivotal randomized study, and they're going to report out data by summer of next year. Where are you with your DLL3, and can you get that going as soon as possible and catch up to all these players?
Yeah, so Mike, DLO3, another great target. We believe ESMO established DLO3, we believe, as the most validated target in small cell lung cancer, as well as neuroendocrine carcinoma through several independent data sets, including the Delphi data and frontline maintenance from Indeltra, our peers' data, as well as ours, where we reported second-line overall survival of over 14 months. In the small cell lung cancer setting, which we think is quite exciting. In addition, Mike, in terms of where we are, we did announce recently that our plan to start two registrational phase three studies by the end of the year, including in the relapsed setting of small cell lung cancer post-Indeltra, which we think is an important point of differentiation, especially now with Indeltra moving into frontline maintenance. And then second, in refractory neuroendocrine carcinoma. So we'll be providing more updates here very shortly on what our specific trial design plans are in NEC.
Just to be clear, you believe that in second-line small cell lung cancer, second-line plus, if you failed parlatumab, Which is, you know, most of the population over the next five or 10 years, that your drug, although it's the same target of DL3, different mechanism of action, that they have not lost the antigen and that your drug should still have plenty of efficacy in a single arm pivotal study or randomized study.
So in later line small cell lung cancer, we believe that likely you would need to pursue a randomized study in the post-indulter setting. In the NEC setting, that answer may be different, and that's what we'll give more color on here shortly in the next several days on our view on that. On post-indulter, post a DLL3 TCE, we do believe you can follow it with another DLL3 agent. We don't believe there's data out there that notes that lowering the expression of DLL3 is going to be a mechanism that we need to be concerned about. Second is that we now are building a growing data set in the post-indulter setting, and we believe we're seeing a very robust response rate. Okay.
We think there's limited evidence yet. The science should be there, but we don't have a lot of data. So this is why when we're going into phase three, we're not totally sure exactly what the response rates are going to be. So we're trying to be probably chemo, but I'm not exactly sure what the response rates are going to be. Um, okay. So, and then lastly, do you plan to have a first line strategy or some sort of combination with a TCE? That's what your other competitors trying to do. And this is a bigger market opportunity. Is that something you'd like to try and do?
Yeah, no, thank you for that question. So yeah, so frontline small cell lung cancer, uh, definitely is in scope for us in terms of a high priority. Uh, we want to be thoughtful that we are doing a trial that we have confidence in, In terms of doing it with a differentiated combination, we do believe in the frontline small cell lung cancer setting that the opportunity is primarily in the induction setting, based on the recent Indultra data and maintenance. So I would say we do have interest in several mechanisms, including T-cell engagers, that won't surprise you, as well as bi-specific IO. So, you know, all we can say is that we're having several conversations on this front, and hopefully you'll hear from us more on what our frontline plans are in the future. Okay.
Thank you very much. Look forward to all the developments in 2027. Obviously, again, R&D Day later today, so tune in. Everyone should tune into that, and look forward to great progress. So thank you very much, Ujira.
0:00 to 31:51 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Thank you so much for joining us on our next session. I'm Michael Yee, Senior Biotechnology Analyst here at UBS, and we're excited to have the Chief Executive Officer of IDEA Biosciences here, Ujira Hata, with us. Idea is an exciting time right now because the company is on the brink of filing and getting potential…
Yujiro Hata: Well, great. First, thank you, Mike, for hosting us, and also congratulations to UBS on the inaugural event in London this week. So idea of biosciences, as you mentioned, 2026 has been a transformational year for us. We filed our first NDA, also reported our…